IP Verse

Anticancer Drug Containing Alpha, Alpha, Alphatrifluorothymidine And Thymidine Phosphorylase Inhibitor - EP1849470

The patent EP1849470 was granted to Taiho Pharmaceutical on Mar 20, 2024. The application was originally filed on Jan 25, 2006 under application number EP06712292A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP1849470

TAIHO PHARMACEUTICAL
Application Number
EP06712292A
Filing Date
Jan 25, 2006
Status
Patent Maintained As Amended
Feb 16, 2024
Publication Date
Mar 20, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMar 21, 2018TER MEER STEINMEISTER & PARTNER -
STADA ARZNEIMITTELMar 21, 2018HAMM & WITTKOPP -

Patent Citations (2) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
OPPOSITIONEP0763529
OPPOSITIONWO2006080327

Non-Patent Literature (NPL) Citations (5) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Dwivedy, S. et al., "Safety and Pharmacokinetics..." Clinical Pharmacology Vol.20.2001
OPPOSITION- GREEN et al., "Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC)", Journal of Clinical Oncology, (20060600), XP055480004
OPPOSITION- Thomas et. at., Proceedings of the American Association of Cancer Research,43,554, #2754, 2002
SEARCH- EMURA TOMOHIRO ET AL, "A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, SPANDIDOS PUBLICATIONS, GR, (20040101), vol. 13, no. 4, ISSN 1107-3756, pages 545 - 549, XP009140488 [A] 1-10 * the whole document *
SEARCH- EMURA TOMOHIRO ET AL, "A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA", INTERNATIONAL JOURNAL OF ONCOLOGY, SPANDIDOS PUBLICATIONS, GR, (20040901), vol. 25, no. 3, ISSN 1019-6439, pages 571 - 578, XP009140446 [A] 1-10 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents